Sort   by:  
 Page size 
UnknownTime-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Not available
S-EPMC12214479 | biostudies-literature
UnknownExploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Not available
S-EPMC12170883 | biostudies-literature
UnknownHoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression.
Not available
S-EPMC8711238 | biostudies-literature
UnknownA Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Not available
S-EPMC8518716 | biostudies-literature
Sort   by:  
 Page size